Some clinical activity was reported for novel tyrosine kinase inhibitors in previously treated patients with GIST
However, the future of TKI combinations for these rare tumours is uncertain
However, the future of TKI combinations for these rare tumours is uncertain
Study findings indicate that the agent is promising as maintenance therapy, but managing its tolerability presents challenges
The positive results of the SPEARHEAD-1 trial which showed durable responses of afamitresgene autoleucel in unresectable or metastatic synovial sarcoma granted FDA accelerated approval
A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of care
Two studies in sarcoma explore the promise of ADCs and theranostics realised in different tumours.
An early-phase trial shows the efficacy of brigimadlin in dedifferentiated and well-differentiated liposarcomas, but confirmation from phase III results is still awaited
In a post hoc analysis of the DeFi trial, a reduction in symptom burden was reported, with benefits occurring early in treated patients
Uninterrupted imatinib is essential to optimise outcomes in metastatic and high-risk resected GIST
Disappointing results were reported from the phase III MANTRA trial, but biomarker-based approaches still offer hope for MDM2 inhibition in solid tumours
Results from four early-phase studies show that combining immune checkpoint inhibitors with other immunotherapies or with TKIs is a potentially efficacious strategy for the treatment of different diseases including GIST and vascular sarcomas
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.